Viking Therapeutics


54 3
Viking Therapeutics (VKTX) stock shot up over 100%, despite the fact that ValueEngine downgraded the company from Strong Buy to Buy.

The stock moved up in response to Madrigal Pharmaceuticals' announcement of successful 36-week results from a Phase 2 study of NonAlcoholic SteatoHepatitis (NASH) candidate MGL-3196, a thyroid hormone receptor-beta agonist. Viking's NASH candidate, Phase 2-stage VK2809, has the same mechanism of action. :clap::clap: